Alibaba Health Information Technology Beheer
Beheer criteriumcontroles 2/4
De CEO Alibaba Health Information Technology is Difan Shen, benoemd in Nov2023, heeft een ambtstermijn van 3.08 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 6.81M, bestaande uit 25.2% salaris en 74.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.009% van de aandelen van het bedrijf, ter waarde HK$ 6.21M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 2.3 jaar.
Belangrijke informatie
Difan Shen
Algemeen directeur
CN¥6.8m
Totale compensatie
| Percentage CEO-salaris | 25.2% |
| Dienstverband CEO | less than a year |
| Eigendom CEO | 0.009% |
| Management gemiddelde ambtstermijn | 2.3yrs |
| Gemiddelde ambtstermijn bestuur | 2.3yrs |
Recente managementupdates
Recent updates
Earnings Tell The Story For Alibaba Health Information Technology Limited (HKG:241) As Its Stock Soars 30%
Oct 18
What Does Alibaba Health Information Technology Limited's (HKG:241) Share Price Indicate?
Sep 23Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31
If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2024 | CN¥7m | CN¥2m | CN¥883m |
| Dec 31 2023 | n/a | n/a | CN¥851m |
| Sep 30 2023 | n/a | n/a | CN¥817m |
| Jun 30 2023 | n/a | n/a | CN¥675m |
| Mar 31 2023 | CN¥6m | CN¥1m | CN¥536m |
| Dec 31 2022 | n/a | n/a | CN¥332m |
| Sep 30 2022 | n/a | n/a | CN¥128m |
| Jun 30 2022 | n/a | n/a | -CN¥69m |
| Mar 31 2022 | CN¥6m | CN¥1m | -CN¥266m |
| Dec 31 2021 | n/a | n/a | -CN¥216m |
| Sep 30 2021 | n/a | n/a | -CN¥167m |
| Jun 30 2021 | n/a | n/a | CN¥91m |
| Mar 31 2021 | n/a | n/a | CN¥349m |
| Dec 31 2020 | n/a | n/a | CN¥313m |
| Sep 30 2020 | n/a | n/a | CN¥278m |
| Jun 30 2020 | n/a | n/a | CN¥136m |
| Mar 31 2020 | CN¥12m | CN¥2m | -CN¥7m |
| Dec 31 2019 | n/a | n/a | -CN¥3m |
| Sep 30 2019 | n/a | n/a | CN¥1m |
| Jun 30 2019 | n/a | n/a | -CN¥40m |
| Mar 31 2019 | CN¥7m | CN¥33k | -CN¥82m |
Compensatie versus markt: De totale vergoeding ($USD 951.23K ) Difan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 576.36K ).
Compensatie versus inkomsten: De vergoeding van Difan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Difan Shen (46 yo)
less than a year
Tenure
CN¥6,814,000
Compensatie
Mr. Difan Shen serves as Chief Executive Officer of Alibaba Health Information Technology Limited from November 28, 2023 and serves as Executive Director since October 13, 2021. He was Chief Operating Offi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | less than a year | CN¥6.81m | 0.0089% HK$ 6.2m | |
| CFO & Executive Director | 4.6yrs | CN¥5.34m | 0.0050% HK$ 3.5m | |
| Legal Counsel & Joint Company Secretary | 1.8yrs | geen gegevens | geen gegevens | |
| Chief Marketing Officer | 2.7yrs | geen gegevens | geen gegevens | |
| Chief People Officer | 4.8yrs | geen gegevens | geen gegevens | |
| Financial Controller | no data | geen gegevens | geen gegevens | |
| Chief Legal Advisor & Joint Company Secretary | 1.3yrs | geen gegevens | geen gegevens |
2.3yrs
Gemiddelde duur
Ervaren management: Het managementteam van 241 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 3.1yrs | CN¥6.81m | 0.0089% HK$ 6.2m | |
| CFO & Executive Director | 4.1yrs | CN¥5.34m | 0.0050% HK$ 3.5m | |
| Independent Non-Executive Director | 1.3yrs | CN¥411.00k | geen gegevens | |
| Independent Non-Executive Director | 5.4yrs | CN¥348.00k | geen gegevens | |
| Non-Executive Chairman of the Board | 4.7yrs | CN¥19.00m | 0.0086% HK$ 6.0m | |
| Independent Non-Executive Director | 1.3yrs | CN¥223.00k | geen gegevens | |
| Non-Executive Director | 1.5yrs | geen gegevens | geen gegevens | |
| Non-Executive Director | 1.1yrs | geen gegevens | geen gegevens |
2.3yrs
Gemiddelde duur
48.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 241 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.